Flush with cash, BMS chief confirms '100% pharma' focus

Bristol-Myers Squibb ($BMY) CEO Lamberto Andreotti (photo) is happy he has $10 billion in cash to spend on small acquisitions that can bolster his pure-pharma strategy. He's especially happy most of it is already in the U.S., rather than subject to repatriation taxes. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.